# Junta clínica — PT-pseudo_6b6ee002f75d (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_6b6ee002f75d",
  "pid": "PT-pseudo_6b6ee002f75d",
  "task": 1,
  "psa": 6.22,
  "age": 65,
  "months": 3,
  "pirads": "5",
  "psad": 0.17,
  "psav": 1.14,
  "psap": 5.6,
  "vol": 36.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.86727,
  "medhx": "Hypertension, Chronic kidney disease",
  "meds": "amlodipine, valsartan",
  "notes": "PSA 6.22 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 36 mL. DRE nodus. csPCa 0.87.",
  "pmhx": [
    "Hypertension",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "75 kg",
    "height": "177 cm",
    "bmi": "23.9",
    "bp": "127/68 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (17 pack-yr, quit 2001)",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "12 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical review requested after previous biopsy confirmed high-grade malignancy alongside recent PSA escalation."
    },
    {
      "s": "History",
      "t": "A 65-year-old retired truck driver has been monitored since the initial PSA elevation was detected in 2022. He resides with his unmarried partner and maintains a vigorous routine, including twice-weekly tennis matches and roughly three units of alcohol weekly. Past medical history encompasses hypertension and stage 3 chronic kidney disease, currently controlled with amlodipine and valsartan. Tobacco use ceased in 2001 following a 17 pack-year exposure. He denies any current urinary complaints, registering an IPSS score of zero. Recent primary care visits included a seasonal influenza vaccination alongside a dermatological screening for a routine actinic keratosis. A decades-old right knee meniscus tear occasionally causes mild aching during cold spells but imposes no functional restrictions. Due to mild hearing impairment, he requests written documentation for all clinical updates."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: A firm, discrete nodule measuring roughly 1 cm in diameter is palpable within the right peripheral zone, while overall gland symmetry remains intact. General inspection reveals no abnormalities; vital parameters record a blood pressure of 127/68 mmHg and a heart rate of 72 bpm. Cognitive status is alert and oriented. Body mass index registers at 23.9 kg/m2. The patient acknowledges mild hearing impairment yet demonstrates clear comprehension of all procedural directives."
    }
  ],
  "occupation": "retired truck driver",
  "marital": "Living with partner (unmarried)",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "GP practice nurse — flu vaccination",
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "3 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_6b6ee002f75d
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 6.22 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.17 ng/mL²
  - PSA velocity: 1.14 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 36.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86727 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Chronic kidney disease
  - Problem list / PMHx: Hypertension, Chronic kidney disease
  - Current medication: amlodipine, valsartan
  - Allergies: NKA
  - Additional notes: PSA 6.22 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 36 mL. DRE nodus. csPCa 0.87.

Vitals: weight 75 kg, height 177 cm, BMI 23.9, BP 127/68 mmHg, HR 72 bpm. Smoking: Ex-smoker (17 pack-yr, quit 2001).

Chief complaint: Clinical review requested after previous biopsy confirmed high-grade malignancy alongside recent PSA escalation.

History: A 65-year-old retired truck driver has been monitored since the initial PSA elevation was detected in 2022. He resides with his unmarried partner and maintains a vigorous routine, including twice-weekly tennis matches and roughly three units of alcohol weekly. Past medical history encompasses hypertension and stage 3 chronic kidney disease, currently controlled with amlodipine and valsartan. Tobacco use ceased in 2001 following a 17 pack-year exposure. He denies any current urinary complaints, registering an IPSS score of zero. Recent primary care visits included a seasonal influenza vaccination alongside a dermatological screening for a routine actinic keratosis. A decades-old right knee meniscus tear occasionally causes mild aching during cold spells but imposes no functional restrictions. Due to mild hearing impairment, he requests written documentation for all clinical updates.

Physical examination: Per rectum: A firm, discrete nodule measuring roughly 1 cm in diameter is palpable within the right peripheral zone, while overall gland symmetry remains intact. General inspection reveals no abnormalities; vital parameters record a blood pressure of 127/68 mmHg and a heart rate of 72 bpm. Cognitive status is alert and oriented. Body mass index registers at 23.9 kg/m2. The patient acknowledges mild hearing impairment yet demonstrates clear comprehension of all procedural directives.

Patient info: retired truck driver; Living with partner (unmarried); Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Tennis 2x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Dermatology — actinic keratosis check.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.48
  uncertainty  +/- 0.10 epistemic (95% band 0.27-0.68); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 65 (2% of my signal; from age) · DRE = Nodus (10% of my signal; from dre_suspicious) · PSA = 6.22 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 36 mL (1% of my signal; from log_vol, vol) · PSA density = 0.17 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.87 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 65 · DRE = Nodus · PSA = 6.22 ng/mL · prostate volume = 36 mL · PSA density = 0.17 · PI-RADS = 5 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.35: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  2. distance 0.44: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"
  3. distance 0.61: PI-RADS 5, PSA 6.9, PSAD 0.257, age 67, DRE Nodus -> BIOPSY (uncertain). He wrote: "What was the result of the earlier positive biopsy and the MRI precluding that biopsy? Hard to determine what we are looking at here."

PRECEDENT: DEFER (weighted vote 0.25 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · DRE = Nodus · PSA = 6.22 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · age = 65 · prostate volume = 36 mL · PSA density = 0.17
  not used   csPCa probability, comorbidity
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 65 · DRE = Nodus · PSA = 6.22 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · prostate volume = 36 mL · PSA density = 0.17 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using a risk-adapted pathway based on PI-RADS score, PSA density, and prior biopsy status. It states, "In a contemporary series of biopsies, the likelihood of finding a csPCa after follow-up biopsy after a diagnosis of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia (PIN) was only 6-8% - not significantly different from follow-up biopsies after a negative biopsy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline makes the variable 'prior biopsy = Positive' context, whereas EXPERT-STRUCTURED marked it as decisive. The guideline suggests that the decision should be based on the risk-adapted matrix involving PI-RADS score and PSA density, rather than solely on the prior biopsy status. The guideline suggests that the decision should be based on the risk-adapted matrix involving PI-RADS score and PSA density, rather than solely on the prior biopsy status. The guideline needs the prior grade of the prior biopsy to determine the next step, which no panel variable represents.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: a rising PSA velocity is a factor that should be considered in the risk-based pathway
laboratory_results - the PSA density: the PSA density is a key component in the risk-based matrix that the guideline makes decisive here

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the documented grade of the prior biopsy and the PSA density to determine the appropriate risk-adapted pathway.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension change compared to an earlier study?
  psa_trend (get_psa_trend) -> Is the PSA velocity rising?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy (Gleason/ISUP), and is there a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> What is the PSA density?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "What is the PSA density?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report: Amsterdam UMC (VUmc) | Radiology | 08 Jan 2025. COMPARISON: new. LESION: PI-RADS 5 lesion in the right peripheral zone. Prostate volume 36.0 mL yielding a PSA density of 0.17 ng/mL/mL.
psa_trend: PSA 2.2 (Apr 2022) rising to 6.22 (Jan 2025), steepest in the last year.
previous_notes: PRIOR GRADE: not recorded. BIOPSY SESSIONS: not recorded. SURVEILLANCE: not recorded. TREATMENT: none recorded.
laboratory_results: PSA 6.2 ng/mL (14 Dec 2024) rising to 6.22 ng/mL (14 Dec 2024), shape: single value.

WHAT I DID NOT OPEN
family-history anamnesis, as it was not required by the plan to answer the immediate questions.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- PI-RADS 5 (from radiology_report)
- Rising PSA velocity (from psa_trend)
AGAINST sampling this patient now:
- Prior biopsy status is not documented in the notes (from previous_notes)

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.22 ng/mL over 4 points spanning 33 months; velocity +1.21 ng/mL per year; doubling time about 27 months.
PROJECTION at 6 months: 8.7 ng/mL, conformal 95% band 2.5-30.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 6.22 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.11 epistemic (95% band 0.26-0.68), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Nodus (5% of my signal; from dre_suspicious) · PSA = 6.22 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 36 mL (4% of my signal; from log_vol, vol) · PSA density = 0.17 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.48  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.47  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.25  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.47 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          65                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Nodus                        E1:not E3:not cohort:not library:IMP E2:—            -> important
  psa          6.22 ng/mL                   E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          36 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.17                         E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.87                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:— E2:—              -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: borderline.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes, laboratory_results) directly address the moderator's questions.

ALIGNMENT WITH THE PANEL
The PANEL-PROTOCOL suggests BIOPSY based on a weighted vote (p=0.47), which aligns with the lean noted by the Registrar based on the rising PSA velocity and PI-RADS 5.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? This question remains unanswered, as the previous_notes explicitly state "PRIOR GRADE: not recorded."

WHAT CARRIES WEIGHT, AND WHY
prior biopsy: Positive (decisive) because the EXPERT-STRUCTURED and EXPERT-FUSION models weighted this highly, despite the lack of documentation. I would move this to 'important' because the lack of documentation is the central ambiguity.
psa: 6.22 ng/mL (important) because the PSA is elevated and the PSA trend is rising, which the EAU guideline considers a factor.
psad: 0.17 (noted) as it is a component of the risk-adapted matrix discussed by the EAU expert.
My confidence in the record as it stands is borderline due to the missing documented prior biopsy grade.

MY SUGGESTION TO THE CHAIR
Given that the documented prior grade is missing, and the EAU guideline emphasizes the documented grade, I suggest deferring to obtain this critical piece of information before proceeding with a biopsy.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

PI-RADS 5 with rising PSA 6.22 ng/mL and no recorded prior biopsy grade mandates sampling for definitive management. Prior grade is not recorded, which is a key missing finding. DRE nodule and age 65 are noted, but the new PI-RADS 5 lesion drives the decision toward biopsy. Alternative plan is further staging and treatment.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
